CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Cue Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$16.08−0.63 (-3.77%)
Close on Oct 19, 2026
- Market cap
- $101.96M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.81 (−32.69%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Cue Biopharma, Inc. grew revenue 354.4% to $37.65M over the twelve months to Jun 30, 2026. Free cash flow was -$50.17M.
Revenue
$37.65M
+354.4% vs. a year earlier
Operating income
-$98.67M
TTM Q2 2026
Free cash flow
-$50.17M
TTM Q2 2026
EPS, diluted
-$26.88
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $101.96M
- P/E ratio
- –
- Price to sales
- 2.71
- Price to book
- 44.14
- Dividend yield
- –
- Free cash flow yield
- -49.20%
Fundamentals
- Revenue
- $37.65M
- Net income
- -$164.11M
- EPS, diluted
- -$26.88
- Free cash flow
- -$50.17M
- Book value per share
- $0.36
- Diluted shares
- 6M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$37.65M+354.4% YoY
Operating income
-$98.67M
Net income
-$164.11M
EPS, diluted
-$26.88
Free cash flow
-$50.17M
Reported periodTrailing twelve months